11/15
11:11 am
gnft
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus [Yahoo! Finance]
Low
Report
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus [Yahoo! Finance]
11/13
04:22 pm
gnft
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 [Yahoo! Finance]
High
Report
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 [Yahoo! Finance]
11/13
04:10 pm
gnft
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
High
Report
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
11/7
04:23 pm
gnft
GENFIT Reports Third Quarter 2024 Financial Information [Yahoo! Finance]
Medium
Report
GENFIT Reports Third Quarter 2024 Financial Information [Yahoo! Finance]
11/7
04:10 pm
gnft
GENFIT Reports Third Quarter 2024 Financial Information
Medium
Report
GENFIT Reports Third Quarter 2024 Financial Information
10/17
03:31 am
gnft
High Growth Tech Stocks in France for October 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks in France for October 2024 [Yahoo! Finance]
10/11
08:41 am
gnft
Genfit S.A. (NASDAQ: GNFT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Medium
Report
Genfit S.A. (NASDAQ: GNFT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
10/2
05:33 pm
gnft
Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight [Yahoo! Finance]
Low
Report
Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight [Yahoo! Finance]
9/23
12:03 pm
gnft
Ipsen's Iqirvo wins European approval for primary biliary cholangitis [Yahoo! Finance]
Low
Report
Ipsen's Iqirvo wins European approval for primary biliary cholangitis [Yahoo! Finance]
9/23
01:30 am
gnft
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
Low
Report
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
9/20
01:29 pm
gnft
Genfit S.A. (NASDAQ: GNFT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Low
Report
Genfit S.A. (NASDAQ: GNFT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
9/20
09:12 am
gnft
Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade [Yahoo! Finance]
Low
Report
Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade [Yahoo! Finance]
9/20
09:02 am
gnft
Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade [Financial Post (Toronto, Ontario, Canada)]
9/19
04:16 pm
gnft
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
9/19
04:10 pm
gnft
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
High
Report
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update